boc val ala pab pnp

Boc-Val-Ala-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. This cleavable compound efficiently facilitates drug-attachment to antibodies, allowing for targeted therapeutic delivery and release, thus playing a crucial role in ADC development.

Boc-Val-Cit-OH is a cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Mc-Val-Ala-PAB, an effective linker, is utilized in antibody-drug-conjugate (ADC).

Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

Val-cit-PAB-OH is an ADC linker that is cleavable.

Fmoc-Val-Cit-PAB is a linker used for antibody-drug-conjugation (ADC).

MC-Val-Cit-PABC-PNP, also known as Mc-Val-Cit-PABC-PNP, is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker. Protein- and peptide-drug conjugates hold a promising stance in the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. Use of specialized linkers makes them unique in their in vivo therapeutic application by providing target tissue-specific release of drug.

MC-Val-Ala-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

Endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable four-unit polyethylene glycol (PEG) linker, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected via the MC-Val-Cit-PAB ADC linker, which endows it with significant antitumor activity.

Mal-PEG4-Val-Cit-PAB-PNP is a cleavable, 4-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-Val-Cit-PAB-OH, a cleavable 4-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Boc-Phe-(Alloc)Lys-PAB-PNP serves as a cleavable linker in the synthesis of antibody-drug conjugates (ADCs).

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker used in the synthesis of ADCs[1].

The chemical compound Mal-Phe-C4-Val-Cit-PAB-DMEA is a cleavable antibody-drug conjugate (ADC) linker that incorporates a Maleimide group. It is commonly employed in the synthesis of ADCs.

OPSS-Val-Cit-PAB-PNP, a cleavable linker used in ADC (antibody-drug conjugates) synthesis [1].

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB is a cleavable three-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate used in antibody-drug conjugates (ADC) that exhibits potent antitumor activity. It employs Retapamulin, a ribosome inhibitor, connected via the ADC linker MC-Val-Cit-PAB.

MC-Val-Cit-PAB-vinblastine is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), featuring vinblastine (a microtubule protein inhibitor) connected through the MC-Val-Cit-PAB [ADC linker].

Fmoc-Ala-Ala-Asn-PABC-PNP is a cleavable peptide ADC linker [1].

Fmoc-Val-Ala-PAB-OH (Fmoc-Val-Ala-PAB) is a useful linker for making Antibody-Drug-Conjugation (ADC) conjugate for targeting drug delivery. It is also utilized in the synthesis of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.

Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA is a double-cleavable PEG linker (3-unit and 4-unit) designed for antibody-drug conjugation (ADC).

Azido-PEG5-Ala-Ala-Asn-PAB is a cleavable 5-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Fmoc-PEG4-Ala-Ala-Asn-PAB is a cleavable four-unit polyethylene glycol (PEG) linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Mal-PEG4-Val-Cit-PAB, a cleavable ADC linker incorporating a Maleimide moiety, finds application in the construction of antibody-drug conjugates (ADCs)[1].

Mal-amido-PEG2-Val-Cit-PAB-OH is a bi-functional polyethylene glycol (PEG) linker, composed of two PEG units, that is cleavable and specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1].

Aloc-D-Ala-Phe-Lys(Aloc)-PAB-PNP is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs), innovative therapeutic agents that combine the targeting ability of antibodies with potent cytotoxic drugs.

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3-unit PEG ADC linker used for synthesizing antibody-drug conjugates (ADCs) [1] and also functions as a PEG-based PROTAC linker for PROTAC synthesis [2].

Azido-PEG3-Val-Cit-PAB-OH is a cleavable three-unit polyethylene glycol (PEG) antibody-drug conjugate (ADC) linker used in ADC synthesis [1].

Azido-PEG4-Val-Cit-PAB-OH is a 4-unit PEG ADC linker and a PEG-based PROTAC linker used in the synthesis of antibody-drug conjugates (ADCs)[1] and PROTACs[2].

Boc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Cbz-Phe-(Alloc)Lys-PAB-PNP, a cleavable linker, is utilized in the design of antibody-drug conjugates (ADCs).

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Fmoc-Phe-Lys(Boc)-PAB-PNP is a cleavable antibody-drug conjugate (ADC) linker utilized in ADC synthesis.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable linker designed specifically for antibody-drug conjugate (ADC) synthesis.

MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker combining the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, thereby enhancing its cancer cell targeting and killing effectiveness.

SC-Val-Cit-PAB is a cleavable ADC linker for antibody-drug conjugates (ADCs).

mDPR(Boc)-Val-Cit-PAB is a cleavable linker used in antibody-drug conjugates (ADCs), which are biopharmaceuticals combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs for targeted cancer therapy [1].

MAL-di-EG-Val-Cit-PAB-MMAE consists of the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, both of which are crucial components of antibody-drug conjugates (ADCs).

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

Azido-PEG3-Ala-Boc, a PEG-based linker for PROTACs, joins two essential ligands necessary for forming PROTAC molecules and enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.